All In Biotech

Drug Trial Radar · NCT06137911

Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.

Safety, Tolerability and Pharmacokinetic Characteristics of JYP0061 in Healthy Adult Subjects After Single and Multiple Doses: a Single-center, Randomized, Double-blind, Placebo-controlled, Phase I Trial

Last checked: Nov 19, 2026Latest source record: Dec 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Sep 26, 2021

Primary completion

Nov 9, 2022

Study completion Nov 9, 2022

Sponsor

Lead sponsor
Guangzhou JOYO Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of JYP0061 in healthy adult subjects. The main questions it aims to answer are: safety and tolerability of JYP0061 in healthy subjects, the pharmacokinetic characteristics after single and multiple doses and the effect of food on the pharmacokinetic characteristics. Participants will be treated with JYP0061 orally and safety and pharmacokinetic evaluations will be conducted according to the protocol.

Conditions

  • Healthy Subjects

Interventions

  • JYP0061Drug

    JYP0061 orally administered

  • placeboDrug

    Placebo orally administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The peak plasma concentration that JYP0061 achieves after dosing.Time frame: up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui District Central Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.